CellRACE: AI-based cell tracking software developed and ready for use
Cline Scientific AB has been collaborating on a project with software company IFLAI to develop custom AI-based software for the cancer diagnostic project, CellRACE. In line with the previous information and timeline set out on the 7th of October, this software has now been developed.
The deep learning software is a fully tailored solution that allows automated cell identification and tracking of cells recorded in Cline experiments. This first-stage project allows Cline to conduct deeper data analysis on millions of data points and to further develop CellRACE into an effective and robust dianogistic product. The new system has the opportunity to be a ground-breaking part of the diagnostic product and lays the foundation for a fully automated system to determine the metastatic risk of a patient’s tumor cells.
The software will now be installed at the Cline labs and the team will conduct a validation and refinement period allowing for the expanded capabilities going forward.
IFLAI, short for Innovations for Life Sciences through Artificial Intelligence, is a spinoff company with researchers from the University of Gothenburg and Chalmers University of Technology. With more than 20 years of experience in microscopy and analysis of complex systems, professors Mattias Goksör and Giovanni Volpe have set out to develop a highly flexible, customizable, reliable, and reproducible automated image analysis software for life science applications, based on cutting-edge scalable AI solutions.
Cline is developing CellRACE, a cell-based cancer diagnostic product that can assess the risk of metastasis. Using the Cline gradient surfaces combined with advanced analytics, CellRACE aims to predict the probability of metastasis in an accurate manner not possible today as well as in a much earlier stage so the patient can start relevant treatment. The product has the potential to be used both in breast cancer diagnosis as well as in other forms of metastasizing cancer.
The analysis method forms part of the overall CellRACE project and its pathway to becoming a marketed product. Once the analytical method and prediction algorithm has been completed, the next milestone in the CellRACE development journey will consist of conducting a pilot study. Following this, continued product development and final product design will be completed before performing the necessary regulatory approval steps, such as a clinical performance evaluation.
For more information, please contact:
Email: [email protected]
Phone: +46 704 88 79 23
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.
AcouSort to present its unique acoustofluidics technology at the international conference µTAS 2023
AcouSort’s technology makes it possible to fractionate the different cell types in a blood sample, isolate extracellular vesicles, or wash cells to remove contaminants, without having any physical contact with the sample. The technology continues to find its way into an increasing number of life sci...
AcouSort presenterar sin unika teknologi för akusto-fluidik den internationella konferensen μTAS 2023
AcouSorts teknologi gör det möjligt att fraktionera de olika celltyperna i ett blodprov, isolera extracellulära vesiklar eller tvätta celler för att avlägsna föroreningar utan fysisk kontakt med provet. Teknologin fortsätter att finna en plats i allt fler life science-tillämpningar. Den 15-19 oktobe...
Brain+ A/S announces the exercise price for its warrants of series TO 2
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICA...
Annexin announces success in the company's cancer initiative
Within the framework of Annexin's cancer initiative, the company has successfully produced a so-called conjugate where the drug candidate ANXV is chemically bound to a chemotherapy agent and together forms a new composite molecule. In cell systems outside the body, this ANXV conjugate has been shown...